Structural Bioinformatics Abstract and indexing Services

Testimonials

Frequently Asked Questions (FAQs)

Placement Assistance

NTHRYS Updates

1. Commence of NTHRYS Abstract and Indexing Services

   NTHRYS Biotech Labs is commencing its Abstract and Indexing Services linking to its own in house build Research Objectives ID (RO) database.. There is a gap for a perfect global research abstract and indexing database which can organise research works based -on their objectives rather than just author given keywords. This is exactly the approach NTHRYS BIOTECH LABS want to execute and bring to reality in its upcoming NTHRYS Research Objectives based Abstract and Indexing (NRO-AI). Systemic Intelligence algorithms are designed to serve the users for this NRO-AI engine.

2. Biopesticides CRY Proteins database completion

   Bacillus thuringiensis produces CRY proteins that are specific to insect gut cell linings. Bt CRY Proteins to their respective Insect Cell Lines specificity database is completed by NTHRYS Team. Its completion has simplified Crop specific biopesticide strains allocation strategy design.

3. Plant Probiotics

   Introducing our Revolutionary Plant Probiotics: Cultivating Greener Futures. Discover our latest endeavor in sustainable agriculture – the launch of our groundbreaking Plant Probiotics product line. Uncover the secrets to healthier, more vibrant plants as we delve into the world of beneficial microorganisms and their transformative effects -on cultivation practices. Stay tuned for updates and insights that will redefine your approach to plant care and contribute to a greener, more sustainable future. Open

4. MDR Research Commencement

   Multi Drug Resistance (MDR) research employs cutting-edge methodologies, like genomics and high-throughput screening, to decipher how drug-resistant pathogens evolve, aiming to uncover new treatment targets and transform global health defenses against these resilient threats. In the realm of combating Multi Drug Resistance (MDR), our research endeavors have evolved to embrace sophisticated methodologies at the frontier of medical innovation. Through an intricate fusion of genomics, proteomics, and high-throughput screening techniques, our approach confronts the formidable challenge posed by drug-resistant pathogens. Employing state-of-the-art molecular assays and computational analyses, our methodologies aim to decipher the underlying mechanisms driving resistance evolution. This pioneering strategy -not -only dissects the intricate pathways of resistance but also seeks to unveil -novel therapeutic targets. By amalgamating diverse scientific disciplines and leveraging the latest technological advancements, our efforts strive to revolutionize the fight against MDR, forging a pathway to safeguard global health.